Arkolith/Insider Trading/ADVM/Form 4

Rubinstein Linda M

CHIEF FINANCIAL OFFICERAdverum Biotechnologies, Inc. (ADVM) · full profile →Form 4 · filed Dec 10, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
5 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 9, 2025Tender(U)8K——0
Dec 9, 2025Grant(A)42K—$042K
Dec 9, 2025Tender(U)42K——0
Dec 9, 2025Tender(U)61K——0
Dec 9, 2025Option exercise(M)49K$4.20$205K61K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 9, 2025Option exercise(M)49K——0
Dec 9, 2025Disposed to issuer(D)62K——0
Dec 9, 2025Disposed to issuer(D)85K——0
Dec 9, 2025Disposed to issuer(D)35K——0

Transaction Codes

U
See SEC Form 4 code table
A
Grant / award
M
Option exercise / conversion
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001321937-25-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML